Humoral reactivity to Hsp60, miosyn and Sgt1 of the sera of newborns with complex congenital heart defect
Currently, many cardiac biomarkers are used in the clinic, including natriuretic peptides and troponins, and many others are under development. The expediency of determining levels of antibodies against heat shock protein 60 (Hsp60) in serum as a safety and effectiveness marker of the autologous cord blood usage in cardiac surgery of infants with the critical congenital heart defect was shown.
Purpose. A comparative study of humoral reactivity to Hsp60, myosin, and Sgt1 of infant’s serum with critical congenital heart disease, which received the transfusion of autologous cord blood or donor blood components during surgical correc-tion of congenital heart.
Materials and methods. 102 infants with transposition of great arteriies were studied: group 1 – 42 patients who received the transfusion of autologous cord blood during the surgery; group 2 – 48 patients who received the transfusion of donor blood components during the surgery. The control group included 21 clinically healthy newborns. The level of IgG antibodies against Hsp60, human myosin, and Sgt1 in serum was determined by ELISA.
Results. It was observed that levels of anti-Hsp60 and anti-Sgt1 antibodies did not increase, but rather decrease in the early postoperative period in patients of group 1. In group 2 patients in the early postoperative period revealed increasing levels of anti-Hsp60 antibody and anti-Sgt1 antibodies in 12,5% (6/48) of cases. In the remote postoperative period, elevated levels of anti-Hsp60 and anti-Sgt1 antibodies were identified only in patients with a congenital defect, which received the blood transfusion of donor’s blood components during surgical correction while antibodies against myosin we detected equally in patients of both groups (22,2% (6/27) and 23,3 % (7/30) respectively).
Conclusion. In the remote postoperative period (2 years), elevated levels of anti-Hsp60 and anti-Sgt1 antibodies were identified only in patients with congenital heart defect, which received the transfusion of donor blood components during surgical correction. The use of donor blood components in a newborn with a congenital heart defect during the surgery, as opposed to autologous cord blood can lead to the development of autoimmune processes in the patient in the remote period after surgery.
2. Застосування анти-Hsp60 антитіл як маркерів імунної безпеки проведення гемотрансфузій у кардіохірургії вроджених вад серця / Ткаченко Я. В., Воробйова Г. М., Сидорчик Л. Л. та ін. // Патент на винахід №103141. Опубл. 10.09.2013, Бюл. № 17.
3. Chlamydya trachomatis infection and anti-Hsp60 immunity: the two sides of the coin / Cappello F., de Macario E., Di Felice V. et al. |// Plos Pathogens. – 2009. – Vol.5, N 8. – P. 1–9.
4. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis / Perschinka H., Mayr M., Millonig G. et al. |// Arteriscler. Thromb. Vasc. Biol. – 2003. – Vol. 23, N 6. – P. 1060–1065.
5. Shoenfeld Y., Gershwin M., Meroni P. Antibodies. – 2007 (Elsevier). – 830 p.
6. Spiechowicz M., Filipek A. The expression and function of Sgt1 protein in eukaryotic cells // Acta Neurobiol. Exp. – 2005. – Vol. 65. – P. 161–165.
7. Получение рекомбинантного шаперона GroEL и его иммунологическая кросс-реактивность с Hsp60 / Капустян Л., Кия мова Р., Гришкова В. и др. // Biopolym. Cell. – 2006. – Vol. 22, N 2. – P. 117–121.
8. Розробка експериментальної моделі аутоімунного міозин-індукованого пошкодження міокарда / Бобик В., Рябенко Д., Сергієчко О. та ін. // Biopolym. Cell. – 2007. – Vol. 23, N 2. – P. 115–121.